Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates

Group 1 - Halozyme Therapeutics reported quarterly earnings of $1.26 per share, exceeding the Zacks Consensus Estimate of$1.16 per share, and showing an increase from $0.82 per share a year ago, representing an earnings surprise of 8.62$298.01 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 4.93%, and up from 230.04 million in the same quarter last year [2] - Halozyme Therapeutics has outperformed the S&P 500, with shares increasing approximately 21.9% since the beginning of the year compared to the S&P 500's gain of 4% [3] Group 2 - The earnings outlook for Halozyme Therapeutics is mixed, with the current consensus EPS estimate for the upcoming quarter at 1.01 on revenues of $247.73 million, and for the current fiscal year at$5.01 on revenues of $1.19 billion [7] - The Medical - Biomedical and Genetics industry, to which Halozyme belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]